CN106999431B - 抗癌组合物 - Google Patents

抗癌组合物 Download PDF

Info

Publication number
CN106999431B
CN106999431B CN201580066233.4A CN201580066233A CN106999431B CN 106999431 B CN106999431 B CN 106999431B CN 201580066233 A CN201580066233 A CN 201580066233A CN 106999431 B CN106999431 B CN 106999431B
Authority
CN
China
Prior art keywords
arn
hpmcas
solid dispersion
formulation
prostate cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580066233.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN106999431A (zh
Inventor
D.M.赫斯特
J.M.沃格恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aragon Pharmaceuticals Inc
Original Assignee
Aragon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52006906&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN106999431(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aragon Pharmaceuticals Inc filed Critical Aragon Pharmaceuticals Inc
Priority to CN202210133724.8A priority Critical patent/CN114886852A/zh
Publication of CN106999431A publication Critical patent/CN106999431A/zh
Application granted granted Critical
Publication of CN106999431B publication Critical patent/CN106999431B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201580066233.4A 2014-12-05 2015-12-03 抗癌组合物 Active CN106999431B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210133724.8A CN114886852A (zh) 2014-12-05 2015-12-03 抗癌组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14196594.7 2014-12-05
EP14196594 2014-12-05
PCT/US2015/063661 WO2016090098A1 (en) 2014-12-05 2015-12-03 Anticancer compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210133724.8A Division CN114886852A (zh) 2014-12-05 2015-12-03 抗癌组合物

Publications (2)

Publication Number Publication Date
CN106999431A CN106999431A (zh) 2017-08-01
CN106999431B true CN106999431B (zh) 2022-03-04

Family

ID=52006906

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580066233.4A Active CN106999431B (zh) 2014-12-05 2015-12-03 抗癌组合物
CN202210133724.8A Pending CN114886852A (zh) 2014-12-05 2015-12-03 抗癌组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210133724.8A Pending CN114886852A (zh) 2014-12-05 2015-12-03 抗癌组合物

Country Status (29)

Country Link
US (3) US20170360754A1 (https=)
EP (2) EP3226841B1 (https=)
JP (2) JP6937692B2 (https=)
KR (2) KR20200141533A (https=)
CN (2) CN106999431B (https=)
AR (1) AR102926A1 (https=)
AU (3) AU2015358490B2 (https=)
BR (1) BR112017011788A2 (https=)
CA (1) CA2969656A1 (https=)
CL (1) CL2017001371A1 (https=)
CO (1) CO2017005572A2 (https=)
CR (1) CR20170216A (https=)
EA (1) EA201791222A1 (https=)
ES (1) ES2996833T3 (https=)
HR (1) HRP20241719T1 (https=)
HU (1) HUE069689T2 (https=)
IL (2) IL252323B (https=)
MA (1) MA41107B1 (https=)
MD (1) MD3226841T2 (https=)
MX (2) MX387933B (https=)
NZ (1) NZ770528A (https=)
PH (1) PH12017500964A1 (https=)
PL (1) PL3226841T3 (https=)
RS (1) RS66323B1 (https=)
SG (1) SG11201704267VA (https=)
SM (1) SMT202400518T1 (https=)
TW (2) TWI754258B (https=)
UA (1) UA120950C2 (https=)
WO (1) WO2016090098A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114886852A (zh) * 2014-12-05 2022-08-12 阿拉贡药品公司 抗癌组合物

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ744456A (en) 2012-09-26 2019-09-27 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
HUE054935T2 (hu) 2014-12-05 2021-10-28 Aragon Pharmaceuticals Inc Rákellenes készítmények
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
WO2020144650A1 (en) 2019-01-10 2020-07-16 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of prostate cancer
KR20210122275A (ko) 2019-01-30 2021-10-08 얀센 파마슈티카 엔.브이. 분자 아형에 기초하여 전립선암을 치료하는 방법
EP3917519A1 (en) 2019-01-30 2021-12-08 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
EP3811932A1 (en) 2019-10-22 2021-04-28 Zentiva K.S. Dosage form of apalutamide
US11723898B2 (en) 2019-11-04 2023-08-15 Aragon Pharmaceuticals, Inc. Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
WO2022049523A1 (en) 2020-09-04 2022-03-10 Aragon Pharmaceuticals, Inc. Methods for treating prostate cancer
WO2022195407A1 (en) 2021-03-19 2022-09-22 Aragon Pharmaceuticals, Inc. Methods for treating prostate cancer
WO2023122842A1 (es) * 2021-12-31 2023-07-06 Gador Limitada Proceso para la preparación de apalutamida, intermediarios de sintesis y la dispersion solida amorfa que la contiene
WO2023152611A1 (en) 2022-02-11 2023-08-17 Aragon Pharmaceuticals, Inc. Apalutamide and relugolix for the treatment of prostate cancer
WO2023209555A1 (en) 2022-04-26 2023-11-02 Aragon Pharmaceuticals, Inc. Approved drug products and methods for treating prostate cancer
CN116183787A (zh) * 2022-12-26 2023-05-30 郑州德迈药业有限公司 醋酸羟丙甲纤维素琥珀酸酯在阿帕他胺溶出检测中的应用以及检测方法
CN121038790A (zh) 2023-03-16 2025-11-28 拜耳消费者护理股份有限公司 用于治疗激素敏感性前列腺癌生化复发患者的雄激素受体拮抗剂
WO2025153768A1 (en) * 2024-01-18 2025-07-24 Nanoform Finland Oyj Composition comprising crystalline nanosized apalutamide
WO2025174375A1 (en) * 2024-02-15 2025-08-21 Aragon Pharmaceuticals, Inc. Anticancer compositions
WO2026052846A1 (en) 2024-09-09 2026-03-12 Synthon B.V. Pharmaceutical formulation comprising apalutamide

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1545421A (zh) * 2001-06-22 2004-11-10 �Ʒ� 包含低溶解度和/或酸敏感的药物以及中和的酸性聚合物的药物组合物
CN1571658A (zh) * 2001-10-15 2005-01-26 阿斯特拉曾尼卡英国有限公司 包含(r)－比卡鲁胺的药物制剂
CN1787808A (zh) * 2002-02-01 2006-06-14 辉瑞产品公司 应用压力喷嘴制备均匀的喷雾干燥固态无定形药物分散体的方法
CN101450212A (zh) * 1997-08-11 2009-06-10 辉瑞产品公司 提高生物利用度的固体药物分散体
CN101454002A (zh) * 2006-03-27 2009-06-10 加利福尼亚大学董事会 用于治疗前列腺癌和与雄激素受体相关的疾病的雄激素受体调节剂
WO2013152342A1 (en) * 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
WO2013184681A1 (en) * 2012-06-07 2013-12-12 Aragon Pharmaceuticals, Inc. Crystalline forms of an androgen receptor modulator
CN105636594A (zh) * 2013-08-12 2016-06-01 托凯药业股份有限公司 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
CN106102716A (zh) * 2014-02-05 2016-11-09 斯洛文尼亚莱柯制药股份有限公司 雄激素受体拮抗剂的固体药物组合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2132449C (en) 1992-03-31 2002-09-10 Susan E. Barrie 17 - substituted steroids useful in cancer treatment
WO2001060410A1 (en) 2000-02-21 2001-08-23 Takeda Chemical Industries, Ltd. Sustained release preparations of physiologically active compound hardly soluble in water and production process and use of the same
CZ20032225A3 (cs) 2001-02-27 2003-11-12 Astrazeneca Ab Farmaceutická formulace
EP1381358B1 (en) 2001-04-02 2006-05-03 Astrazeneca AB Solid pharmaceutical composition comprising 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide and pvp
WO2003077827A1 (en) 2002-03-19 2003-09-25 Nippon Shinyaku Co., Ltd. Process for producing drug solid dispersion
AU2003292509B2 (en) 2003-12-15 2007-08-02 Council Of Scientific And Industrial Research Taste masked pharmaceutical compositions comprising bitter drug and pH sensitive polymer
GB0502790D0 (en) 2005-02-10 2005-03-16 Univ London Pharmacy Solid dispersion of hydrophobic bioactive
NZ564223A (en) 2005-05-13 2011-03-31 Univ California Diarylhydantoin compounds for treating hormone refractory prostate cancer
MY172424A (en) 2009-04-03 2019-11-25 Hoffmann La Roche Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
AU2011218173C1 (en) 2010-02-16 2015-04-16 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
CN102525876B (zh) 2010-12-15 2014-03-12 西安力邦医药科技有限责任公司 阿司匹林固体分散体、其制备方法、药物组合物和用途
WO2012174436A1 (en) 2011-06-15 2012-12-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nuclear receptor modulators and their use for the treatment and prevention of cancer
US20150037407A1 (en) 2012-03-21 2015-02-05 Emphascience, Inc. Method to improve the safety of handling of high potency drugs in solid dosage forms without changing their efficacy
US10668156B2 (en) 2012-06-22 2020-06-02 Basf Se Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers
MX2015002430A (es) * 2012-08-24 2015-06-22 Dow Global Technologies Llc Acetato-succinatos de hidroxialquilmetilcelulosa.
JP6404217B2 (ja) 2012-09-11 2018-10-10 メディベイション プロステイト セラピューティクス エルエルシー エンザルタミドの製剤
US9977033B2 (en) 2012-09-11 2018-05-22 The Board Of Regents Of The University Of Texas System Methods for assessing cancer recurrence
NZ744456A (en) * 2012-09-26 2019-09-27 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
PL2945628T3 (pl) 2013-01-15 2020-09-21 Aragon Pharmaceuticals, Inc. Modulator receptorów androgenowych w skojarzeniu z octanem abirateronu i prednizonem do leczenia nowotworu stercza
WO2014114575A1 (en) 2013-01-22 2014-07-31 F. Hoffmann-La Roche Ag Pharmaceutical composition with improved bioavailability
US20140287039A1 (en) 2013-03-15 2014-09-25 Iceutica Inc. Abiraterone Acetate Formulation
WO2014167428A2 (en) 2013-04-10 2014-10-16 Shilpa Medicare Limited Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
US9566280B2 (en) 2014-01-28 2017-02-14 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
TWI803187B (zh) 2014-08-08 2023-05-21 日商中外製藥股份有限公司 包含４環性化合物的非晶質體之固體分散體及製劑
HUE054935T2 (hu) 2014-12-05 2021-10-28 Aragon Pharmaceuticals Inc Rákellenes készítmények
LT3226842T (lt) 2014-12-05 2021-03-25 Aragon Pharmaceuticals, Inc. Priešvėžinės kompozicijos
SG11201704267VA (en) * 2014-12-05 2017-06-29 Aragon Pharmaceuticals Inc Anticancer compositions
CA3024872A1 (en) 2016-06-03 2017-12-07 Aragon Pharmaceuticals, Inc. Anticancer compositions
EP3812378A4 (en) 2018-06-20 2021-04-28 Crystal Pharmaceutical (Suzhou) Co., Ltd. CRYSTALLINE FORMS OF RNA-509, CORRESPONDING METHOD OF PREPARATION AND ASSOCIATED USE
EP3811932A1 (en) 2019-10-22 2021-04-28 Zentiva K.S. Dosage form of apalutamide

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101450212A (zh) * 1997-08-11 2009-06-10 辉瑞产品公司 提高生物利用度的固体药物分散体
CN1545421A (zh) * 2001-06-22 2004-11-10 �Ʒ� 包含低溶解度和/或酸敏感的药物以及中和的酸性聚合物的药物组合物
CN1571658A (zh) * 2001-10-15 2005-01-26 阿斯特拉曾尼卡英国有限公司 包含(r)－比卡鲁胺的药物制剂
CN1787808A (zh) * 2002-02-01 2006-06-14 辉瑞产品公司 应用压力喷嘴制备均匀的喷雾干燥固态无定形药物分散体的方法
CN101454002A (zh) * 2006-03-27 2009-06-10 加利福尼亚大学董事会 用于治疗前列腺癌和与雄激素受体相关的疾病的雄激素受体调节剂
WO2013152342A1 (en) * 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
WO2013184681A1 (en) * 2012-06-07 2013-12-12 Aragon Pharmaceuticals, Inc. Crystalline forms of an androgen receptor modulator
CN105636594A (zh) * 2013-08-12 2016-06-01 托凯药业股份有限公司 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
CN106102716A (zh) * 2014-02-05 2016-11-09 斯洛文尼亚莱柯制药股份有限公司 雄激素受体拮抗剂的固体药物组合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
羟丙甲纤维素醋酸琥珀酸酯的研究和应用进展;荀哲，等;《第二届中药现代化新剂型新技术国际学术会议》;20061231;第299-304页 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114886852A (zh) * 2014-12-05 2022-08-12 阿拉贡药品公司 抗癌组合物
US12303493B2 (en) 2014-12-05 2025-05-20 Aragon Pharmaceuticals, Inc. Anticancer compositions

Also Published As

Publication number Publication date
EA201791222A1 (ru) 2017-09-29
TW201630592A (zh) 2016-09-01
MD3226841T2 (ro) 2025-06-30
EP3226841B1 (en) 2024-10-09
KR20170086656A (ko) 2017-07-26
JP7174006B2 (ja) 2022-11-17
EP3226841A1 (en) 2017-10-11
TWI754258B (zh) 2022-02-01
HRP20241719T1 (hr) 2025-02-14
UA120950C2 (uk) 2020-03-10
JP2017536398A (ja) 2017-12-07
JP6937692B2 (ja) 2021-09-22
AU2015358490A1 (en) 2017-06-08
MX387933B (es) 2025-03-19
CN106999431A (zh) 2017-08-01
SG11201704267VA (en) 2017-06-29
EP4494636A3 (en) 2025-04-30
IL252323A0 (en) 2017-07-31
IL279833B (en) 2022-03-01
TW202031248A (zh) 2020-09-01
CA2969656A1 (en) 2016-06-09
HUE069689T2 (hu) 2025-04-28
CO2017005572A2 (es) 2017-09-20
NZ731963A (en) 2024-03-22
AU2021201979B2 (en) 2023-02-02
US12303493B2 (en) 2025-05-20
BR112017011788A2 (pt) 2017-12-26
CN114886852A (zh) 2022-08-12
AR102926A1 (es) 2017-04-05
AU2015358490B2 (en) 2021-04-08
KR102348320B1 (ko) 2022-01-10
US20170360754A1 (en) 2017-12-21
MA41107A (fr) 2017-10-10
TWI702966B (zh) 2020-09-01
MA41107B1 (fr) 2025-01-31
KR20200141533A (ko) 2020-12-18
PL3226841T3 (pl) 2025-03-03
CL2017001371A1 (es) 2018-01-05
CR20170216A (es) 2017-08-30
NZ770528A (en) 2024-03-22
WO2016090098A1 (en) 2016-06-09
RS66323B1 (sr) 2025-01-31
IL279833A (en) 2021-01-31
EP3226841C0 (en) 2024-10-09
JP2020143069A (ja) 2020-09-10
ES2996833T3 (en) 2025-02-13
AU2021201979A1 (en) 2021-04-29
US20230233529A1 (en) 2023-07-27
AU2023202710A1 (en) 2023-05-18
EP4494636A2 (en) 2025-01-22
PH12017500964A1 (en) 2017-10-18
IL252323B (en) 2021-04-29
SMT202400518T1 (it) 2025-01-14
MX2017007203A (es) 2017-08-28
US20240293374A1 (en) 2024-09-05
MX2021013965A (es) 2022-01-04

Similar Documents

Publication Publication Date Title
CN106999431B (zh) 抗癌组合物
CN115837010B (zh) 抗癌组合物
TW201808287A (zh) 抗癌組成物
HK40078336A (en) Anticancer compositions
HK1241764B (en) Anticancer compositions
HK1241764A1 (en) Anticancer compositions
HK1241758A1 (en) Anticancer compositions
HK40003050A (en) Anticancer compositions
EA043321B1 (ru) Противораковая композиция

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1241764

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment

Free format text: NEW EXPIRY DATE: 20360504